The ages of the sufferers ranged from 9 weeks to 61 years . Over fifty % the patients had been between 13 and 47 years, and 90 percent were less than 52 years. Nine individuals were male. All sufferers resided in the Mexico City greater metropolitan region. None of the patients had a history of pneumococcal vaccination. Among the 14 patients whose occupation was documented, 6 were students, 2 were taxi drivers, 3 were housekeepers, 1 was a locksmith, 1 was an employee of a billiards parlor, and 1 was your physician who didn’t have clinical responsibilities and had not been an INER employee. The time between onset of symptoms and admission to the hospital ranged from 4 to 25 days .At that time, despite the continuing partial response of multiple mesenteric and peritoneal lesions, growth of three lesions was noted. In December 2008, further growth of these masses occurred, and the patient subsequently underwent exploratory laparotomy to resect the growing lesions with maximal debulking . After he previously recovered from the operation and with approval from the sponsor and the institutional review plank, treatment with crizotinib was restarted at a dosage of 250 mg twice daily, which had been defined as the maximum tolerated dose.of September 2010 15 As, he remained in complete radiographic remission. While getting crizotinib, the individual has already established edema in the legs and feet, intermittent joint aches, hypocalcemia, hypophosphatemia, leukopenia, and anemia, all of grade 1 intensity, based on the National Malignancy Institute’s Common Terminology Criteria for Adverse Events, version 3.0 and hasn’t acquired aminotransferase elevations, a finding that has complicated the treatment training course in a small percent of patients.15 Patient 2 was a 21-year-old man who offered vomiting and new-onset jaundice in November 2007.